Bright Minds Biosciences Inc. announced on November 21, 2024, that it would present two poster presentations on BMB-101 at the American Epilepsy Society 2024 Annual Meeting in Los Angeles in December. The presentations will focus on the 5-HT2C functional selectivity of BMB-101.
Additionally, the company plans to share Phase 1 clinical data for BMB-101 during the meeting. These presentations are intended to provide further insights into the drug's profile and its progress through early-stage clinical development.
BMB-101 is Bright Minds' lead candidate, a highly selective 5-HT2 agonist being developed for the treatment of drug-resistant epilepsy and other central nervous system disorders. The data presented will contribute to the understanding of its potential therapeutic benefits.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.